Nothing Special   »   [go: up one dir, main page]

LU93073I2 - Acide benzoïque 3-{6-{-1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl¦amino}-3-methylpyridin-2-yl}, ou un sel pahrmaceutiquement acceptable de celui-ci, ou un promédicament de type ester de celui-ci - Google Patents

Acide benzoïque 3-{6-{-1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl¦amino}-3-methylpyridin-2-yl}, ou un sel pahrmaceutiquement acceptable de celui-ci, ou un promédicament de type ester de celui-ci Download PDF

Info

Publication number
LU93073I2
LU93073I2 LU93073C LU93073C LU93073I2 LU 93073 I2 LU93073 I2 LU 93073I2 LU 93073 C LU93073 C LU 93073C LU 93073 C LU93073 C LU 93073C LU 93073 I2 LU93073 I2 LU 93073I2
Authority
LU
Luxembourg
Prior art keywords
prodruce
cyclopropanecarbonyl
benzodioxol
methylpyridin
difluoro
Prior art date
Application number
LU93073C
Other languages
English (en)
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37766297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93073(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of LU93073I2 publication Critical patent/LU93073I2/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/12—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
LU93073C 2005-11-08 2016-05-17 Acide benzoïque 3-{6-{-1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl¦amino}-3-methylpyridin-2-yl}, ou un sel pahrmaceutiquement acceptable de celui-ci, ou un promédicament de type ester de celui-ci LU93073I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73450605P 2005-11-08 2005-11-08
US75408605P 2005-12-27 2005-12-27
US80245806P 2006-05-22 2006-05-22
EP06837028.7A EP1945632B1 (fr) 2005-11-08 2006-11-08 Modulateurs hétérocycliques de transporteurs à cassette liant l' atp

Publications (1)

Publication Number Publication Date
LU93073I2 true LU93073I2 (fr) 2016-07-18

Family

ID=37766297

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93073C LU93073I2 (fr) 2005-11-08 2016-05-17 Acide benzoïque 3-{6-{-1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl¦amino}-3-methylpyridin-2-yl}, ou un sel pahrmaceutiquement acceptable de celui-ci, ou un promédicament de type ester de celui-ci

Country Status (24)

Country Link
US (18) US7741321B2 (fr)
EP (6) EP2774925B1 (fr)
JP (4) JP5317184B2 (fr)
KR (6) KR20150041174A (fr)
CN (2) CN101356170B (fr)
AU (1) AU2006311650B2 (fr)
CA (1) CA2627358C (fr)
CY (3) CY1115750T1 (fr)
DK (4) DK2774925T3 (fr)
ES (5) ES2619608T3 (fr)
HK (2) HK1125366A1 (fr)
HU (2) HUE032640T2 (fr)
IL (2) IL191141A (fr)
LT (2) LT2774925T (fr)
LU (1) LU93073I2 (fr)
NL (1) NL300812I2 (fr)
NO (1) NO20082674L (fr)
NZ (1) NZ567892A (fr)
PL (4) PL1945632T3 (fr)
PT (4) PT2404919E (fr)
RU (3) RU2463303C3 (fr)
SI (4) SI2774925T1 (fr)
WO (1) WO2007056341A1 (fr)
ZA (1) ZA200803887B (fr)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
RU2006111093A (ru) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
CA2545719A1 (fr) * 2003-11-14 2005-06-02 Vertex Pharmaceuticals Incorporated Thiazoles et oxazoles utiles en tant que modulateurs de transporteurs de type cassette de liaison a l'atp
FR2864083B1 (fr) * 2003-12-18 2007-04-13 Galderma Res & Dev Nouveaux derives d'acides phenyl-boroniques et leurs procedes de preparation.
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
MXPA06008606A (es) * 2004-01-30 2007-04-13 Vertex Pharma Moduladores de transportadores con casete de union a atp.
PT1773816E (pt) 2004-06-24 2015-04-29 Vertex Pharma Moduladores de transportadores de cassete de ligação de atp
KR101436161B1 (ko) 2005-01-25 2014-09-01 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
MX2008002019A (es) 2005-08-11 2008-04-16 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
US20120232059A1 (en) * 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
SI2774925T1 (sl) 2005-11-08 2017-04-26 Vertex Pharmaceuticals Incorporated Heterociklični modulatorji prenašalcev z ATP-vezavno kaseto
PL1993360T3 (pl) 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7691902B2 (en) * 2005-12-28 2010-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) * 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
SI3327016T1 (sl) 2006-04-07 2021-09-30 Vertex Pharmaceuticals Incorporated Priprava modulatorjev prenašalcev z ATP-vezavno kaseto
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CA2684105C (fr) 2007-05-03 2011-09-06 Pfizer Limited Derives de la pyridine
CN102863432B (zh) 2007-05-09 2016-09-07 沃泰克斯药物股份有限公司 Cftr调节剂
AU2013231028B2 (en) * 2007-05-09 2016-05-26 Vertex Pharmaceuticals Incorporated Modulators of CFTR
MX2009012678A (es) * 2007-05-25 2012-09-20 Vertex Pharma Moduladores de canal de ion y metodos de uso.
JP5389030B2 (ja) 2007-08-24 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
ES2658064T3 (es) 2007-11-16 2018-03-08 Vertex Pharmaceuticals Incorporated Moduladores de isoquinolina de transportadores de casete de unión a ATP
AU2013231151B2 (en) * 2007-11-16 2015-06-25 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of ATP-Binding Cassette transporters
EP2222638A2 (fr) * 2007-11-21 2010-09-01 Decode Genetics EHF Inhibiteurs de pde4 biaryle pour traiter une inflammation
DK3170818T3 (da) * 2007-12-07 2020-04-14 Vertex Pharma Faste former af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
KR101674404B1 (ko) 2007-12-07 2016-11-09 버텍스 파마슈티칼스 인코포레이티드 사이클로알킬카복시아미도-피리딘 벤조산의 제조 방법
US20100036130A1 (en) * 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
AU2016200431B2 (en) * 2007-12-07 2017-08-24 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2016204422B2 (en) * 2007-12-07 2017-11-16 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
AU2013205160B2 (en) * 2007-12-07 2016-05-19 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2237768A2 (fr) * 2007-12-07 2010-10-13 Vertex Pharmaceuticals Incorporated Formulations d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
AU2013231109B2 (en) * 2007-12-07 2015-10-29 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN106432213A (zh) * 2008-02-28 2017-02-22 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
AU2015228930B2 (en) * 2008-02-28 2017-02-23 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
AU2013205162B2 (en) * 2008-02-28 2015-07-09 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
ES2552990T3 (es) * 2008-03-31 2015-12-03 Vertex Pharmaceuticals Incorporated Derivados de piridilo como moduladores del CFTR
AU2013270464B2 (en) * 2008-03-31 2016-05-26 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
CN102123729B (zh) 2008-06-26 2015-04-29 奥菲泽米有限公司 Hsp70作为酶促活性调节物的应用
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2010018836A2 (fr) * 2008-08-11 2010-02-18 独立行政法人科学技術振興機構 Inhibiteur de l'agrégation des polyglutamines
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
CN102164587A (zh) * 2008-09-29 2011-08-24 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的剂量单元
ES2483690T3 (es) 2008-10-23 2014-08-07 Vertex Pharmaceuticals Incorporated Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
SG174410A1 (en) 2009-03-20 2011-11-28 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
EP2813227A1 (fr) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions pour le traitement de la mucoviscidose et d'autres maladies chroniques
US20130004477A1 (en) * 2009-10-26 2013-01-03 Zhe Lu Methods for Treating Inflammation and Oxidative Stress Related Diseases
KR101419157B1 (ko) * 2009-12-31 2014-07-11 노파르티스 아게 피라진 유도체 및 신경계 장애의 치료에서의 그의 용도
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
US8507687B2 (en) 2010-04-07 2013-08-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
KR20130056244A (ko) 2010-04-22 2013-05-29 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
CA2796646A1 (fr) * 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
WO2011133953A1 (fr) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
WO2011133951A1 (fr) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
EP2560488B1 (fr) 2010-04-23 2015-10-28 Cytokinetics, Inc. Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AU2011248579A1 (en) 2010-04-27 2012-11-29 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2011139489A2 (fr) 2010-04-27 2011-11-10 Calcimedica Inc. Composés capables de moduler le calcium intracellulaire
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2012072082A1 (fr) 2010-11-30 2012-06-07 Orphazyme Aps Procédés pour accroître l'activité cellulaire de hsp70
CN102133402B (zh) * 2011-03-24 2013-06-12 首都医科大学附属北京同仁医院 囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用
US20120316182A1 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
BR112014004845A2 (pt) 2011-08-30 2017-04-04 Chdi Foundation Inc pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
KR102181011B1 (ko) 2011-08-30 2020-11-20 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
US9856240B2 (en) 2011-10-19 2018-01-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6072056B2 (ja) 2011-11-08 2017-02-01 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｐ−結合カセットトランスポーターの修飾因子
TWI640519B (zh) * 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Ｈｅｃ１活性調控因子及其調節方法
EP2806859B1 (fr) 2012-01-25 2019-05-15 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de l'acide 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yle) cyclopropane carboxamido)-3-méthylpyridin-2-yle) benzoïque et leur administration
IL265430B2 (en) 2012-02-27 2024-08-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2872122A1 (fr) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide et son administration
EP2885301A1 (fr) 2012-08-17 2015-06-24 Bayer CropScience AG Amides d'acide azaindole-carboxylique et thiocarboxylique comme insecticides et acaricides
FI2914248T4 (fi) 2012-11-02 2023-12-19 Vertex Pharma Farmaseuttisia koostumuksia cftr-välitteisten tautien hoitamiseksi
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
US20140371238A1 (en) * 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
WO2014141064A1 (fr) 2013-03-13 2014-09-18 Novartis Ag Molécules de liaison à notch2 pour le traitement de maladies respiratoires
CN105307655B (zh) 2013-03-13 2019-05-03 弗拉特利发现实验室有限责任公司 哒嗪酮化合物及其用于制备治疗囊肿状纤维化的药物的应用
WO2014186704A2 (fr) * 2013-05-17 2014-11-20 N30 Pharmaceuticals, Inc. Nouveaux composés permettant le traitement de la fibrose kystique
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
WO2015073231A1 (fr) 2013-11-12 2015-05-21 Vertex Pharmaceuticals Incorporated Procédé de préparation de compositions pharmaceutiques pour le traitement de maladies à médiation assurée par le cftr
CN103664796A (zh) * 2013-12-06 2014-03-26 辽宁师范大学 5-[2-(5-羧基-嘧啶基)]-1,3-苯二羧酸的合成方法
WO2015143376A1 (fr) * 2014-03-21 2015-09-24 Nivalis Therapeutics, Inc. Nouveaux composés destinés au traitement de la mucoviscidose
FI3925607T3 (fi) 2014-04-15 2023-08-28 Vertex Pharma Farmaseuttisia koostumuksia kystisen fibroosin transmembraanisen konduktanssinsäätäjän välittämien tautien hoitamiseksi
EP2932966A1 (fr) 2014-04-16 2015-10-21 Novartis AG Inhibiteurs de la gamma sécrétase pour traiter des maladies respiratoires
ES2747633T3 (es) 2014-07-17 2020-03-11 Chdi Foundation Inc Combinación de inhibidor KMO 6-(3-cloro-4-ciclopropoxifenilo)pirimidina-4-ácido carboxílico con un agente antiviral para el tratamiento de trastornos neurológicos relacionados con VIH
GB201415381D0 (en) 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
AU2015317447B2 (en) 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
ES2702288T3 (es) 2014-10-07 2019-02-28 Vertex Pharma Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
US10308648B2 (en) * 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
KR102509720B1 (ko) 2014-10-31 2023-03-15 애브비 에스.에이.알.엘. 치환된 크로만 및 이의 사용 방법
JP6494757B2 (ja) 2014-11-18 2019-04-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ハイスループット試験高速液体クロマトグラフィーを行うプロセス
MA41587A (fr) 2014-12-17 2021-04-28 Pimco 2664 Ltd N-(4-hydroxy-4-méthylcyclohexyl)-4-phénylbenzènesulfonamides et n-(4-hydroxy-4-méthylcyclohexyl)-4-(2-pyridyl)benzènesulfonamides et leur utilisation thérapeutique
PL3778595T3 (pl) 2015-02-27 2022-04-19 Calcimedica, Inc. Leczenie zapalenia trzustki
GB201504878D0 (en) 2015-03-23 2015-05-06 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
FR3035105A1 (fr) * 2015-04-16 2016-10-21 Metabrain Res Derives utiles dans le traitement de l'atrophie musculaire
JP6936796B2 (ja) 2015-07-06 2021-09-22 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼのヘテロハロ阻害剤
EP3319968A1 (fr) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. N-aminophényl-amides hétérocycliques en tant qu'inhibiteurs de l'histone désacétylase
CA2995094A1 (fr) 2015-08-07 2017-02-16 Calcimedica, Inc. Utilisation d'inhibiteurs du canal crac pour le traitement d'un accident vasculaire cerebral et d'une lesion cerebrale traumatique
CN106432209A (zh) * 2015-08-11 2017-02-22 苏州晶云药物科技有限公司 Lumacaftor的新晶型及其制备方法
US10479782B2 (en) * 2015-09-29 2019-11-19 Mylan Laboratories Limited Forms of lumacaftor and processes for the preparation thereof
GB201517639D0 (en) 2015-10-06 2015-11-18 Algipharma As Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
MA43169B1 (fr) 2015-11-06 2022-05-31 Incyte Corp Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
WO2017118915A1 (fr) * 2016-01-04 2017-07-13 Dr. Reddy's Laboratories Limited Formes solides amorphes et cristallines du lumacaftor ou son complexe et leurs procédés de préparation
US20170190689A1 (en) 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
CN107033120B (zh) * 2016-02-03 2020-03-17 苏州旺山旺水生物医药有限公司 2-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)乙氰的制备方法
WO2017137900A1 (fr) 2016-02-10 2017-08-17 Lupin Limited Lumacaftor amorphe et sa dispersion solide
WO2017141927A1 (fr) * 2016-02-15 2017-08-24 大正製薬株式会社 Composé de pyridine à substituant azole
WO2017175161A1 (fr) * 2016-04-07 2017-10-12 Dr. Reddy’S Laboratories Limited Formes solides de lumacaftor et de ses sels, et procédés associés
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
KR101683011B1 (ko) 2016-04-20 2016-12-07 에스텍전자 주식회사 플렉시블 필름히터를 적용한 온수모듈장치 및 이를 구비하는 온수매트
US10206915B2 (en) 2016-04-25 2019-02-19 Druggability Technologies Ip Holdco Limited Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600271A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
US10376501B2 (en) 2016-04-25 2019-08-13 Druggability Technologies Ip Holdco Limited Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600269A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei
US10383865B2 (en) 2016-04-25 2019-08-20 Druggability Technologies Ip Holdco Limited Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
US20190111041A1 (en) 2016-04-29 2019-04-18 Orphazyme A/S Arimoclomol for treating glucocerebrosidase associated disorders
WO2017223414A1 (fr) 2016-06-24 2017-12-28 Incyte Corporation Composants hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-y
EP3551622B1 (fr) * 2016-12-09 2020-10-07 Vertex Pharmaceuticals Incorporated Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
US10844048B2 (en) 2017-01-09 2020-11-24 Laurus Labs Limited Process and crystalline forms of lumacaftor
DK3570834T3 (en) 2017-01-11 2022-02-28 Alkermes Inc Bicyclic inhibitors of histone deacetylase
CN108658851B (zh) * 2017-03-27 2023-06-06 山东特珐曼药业有限公司 2-氯-3-甲基-6-酰基氨基吡啶及其制备方法和用途
PT3664802T (pt) 2017-08-07 2022-05-24 Alkermes Inc Inibidores bicíclicos de histona-desacetilase
CA3020592A1 (fr) 2017-10-17 2019-04-17 Apotex Inc. Nouvelle forme cristalline de lumacaftor
WO2019136314A1 (fr) 2018-01-05 2019-07-11 The Curators Of The University Of Missouri Composés et méthodes de traitement de la fibrose kystique
WO2019148195A2 (fr) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Inhibiteurs peptidyliques cycliques du domaine de liaison cal-pdz
CN110950807B (zh) * 2018-09-26 2023-03-03 中国科学院上海药物研究所 联芳基类化合物、其制备方法、药物组合物及其应用
WO2020214921A1 (fr) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Formes solides de modulateurs de cftr
US11465982B2 (en) * 2019-07-22 2022-10-11 Boehringer Ingelheim International Gmbh Pyridazines
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
BR112022002605A2 (pt) 2019-08-14 2022-05-03 Vertex Pharma Formas cristalinas de moduladores de cftr
CN114585628B (zh) 2019-08-14 2024-03-26 弗特克斯药品有限公司 囊性纤维化跨膜传导调节因子的调节剂
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP3970718A1 (fr) 2020-09-18 2022-03-23 Charité - Universitätsmedizin Berlin Nouvelle utilisation médicale des modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique (cftr)
US20230374038A1 (en) 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076628A1 (fr) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
US20230365587A1 (en) 2020-10-07 2023-11-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN116783204A (zh) 2020-10-07 2023-09-19 弗特克斯药品有限公司 囊性纤维化跨膜传导调控因子的调节剂
AU2021358512A1 (en) 2020-10-07 2023-05-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225446A1 (fr) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
US20230416275A1 (en) 2020-10-07 2023-12-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2021356651A1 (en) 2020-10-07 2023-05-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225750A1 (fr) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
US20230373935A1 (en) 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230416224A1 (en) 2020-11-19 2023-12-28 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
AU2023215272A1 (en) 2022-02-03 2024-08-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2023150236A1 (fr) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Procédés de préparation et formes cristallines de (6a,12a)-17-amino-12-méthyl-6,15-bis(trifluorométhyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadéca-1(18),2,4,14,16-pentaén-6-ol
WO2023154291A1 (fr) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
AU2023249173A1 (en) 2022-04-06 2024-10-03 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224931A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
AU2023272562A1 (en) 2022-05-16 2024-11-07 Vertex Pharmaceuticals Incorporated Solid forms of a macrocyclic compounds as cftr modulators and their preparation
WO2024056791A1 (fr) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Association de modulateurs de cftr macrocycliques avec des correcteurs de cftr et/ou des potentialisateurs de cftr
WO2024056798A1 (fr) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Modulateurs du cftr macrocycliques
WO2024072793A1 (fr) * 2022-09-26 2024-04-04 Rectify Pharmaceuticals, Inc. Composés de pyridine carboxamide et leur utilisation dans le traitement de pathologies médicales
WO2024072794A1 (fr) * 2022-09-26 2024-04-04 Rectify Pharmaceuticals, Inc. Composés de pyridine carboxamide et leur utilisation dans le traitement de pathologies médicales

Family Cites Families (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758475A (en) 1971-07-20 1973-09-11 Sandoz Ag Pyrido(2,3-d)pyrimidin 2 ones
IT1226048B (it) * 1981-12-14 1990-12-10 Medea Res Srl Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative
DE3263567D1 (en) 1981-12-14 1985-06-20 Medea Res Srl New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
EP0278374A3 (fr) 1987-02-06 1989-03-01 Pharmatest Apparatebau Gmbh Dispositif de détermination de la libération de composants actifs par des produits pharmaceutiques
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5981714A (en) 1990-03-05 1999-11-09 Genzyme Corporation Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
JP3167762B2 (ja) 1990-11-27 2001-05-21 武田薬品工業株式会社 ピリドピリダジン誘導体およびその用途
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
CA2107196A1 (fr) 1992-09-29 1994-03-30 Mitsubishi Chemical Corporation Derives de carboxamide
US6060024A (en) 1993-07-14 2000-05-09 Zymark Corporation Automatic dissolution testing system
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
DE69416848T2 (de) 1993-10-21 1999-07-08 G.D. Searle & Co., Chicago, Ill. Amidino-derivate als no-synthetase inhibitoren
DE4405712A1 (de) 1994-02-23 1995-08-24 Basf Ag Substituierte Naphthyridine und deren Verwendung
RU2114844C1 (ru) 1994-04-11 1998-07-10 Санкио Компани Лимитед Производные тиозолидиндиона или их фармацевтически приемлемые соли, фармацевтическая композиция на их основе и способ лечения или профилактики заболеваний
WO1996010027A1 (fr) 1994-09-27 1996-04-04 Janssen Pharmaceutica N.V. Derives benzoates bicycliques de piperidinyle n-substitue
US6063260A (en) 1994-10-28 2000-05-16 Neurosearch A/S Patch clamp apparatus and technique having high throughput and low fluid volume requirements
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JP2000507955A (ja) 1996-04-03 2000-06-27 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
AU4159297A (en) 1996-08-23 1998-03-06 Agouron Acquisition Corp. Neuropeptide-y ligands
AU6013998A (en) 1996-12-30 1998-07-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US5948814A (en) 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
WO1998047868A1 (fr) 1997-04-18 1998-10-29 Smithkline Beecham Plc Derives d'uree contenant un heterocycle utilises comme antagonistes des recepteurs 5ht1a, 5ht1b et 5ht¿1d?
IL135177A0 (en) 1997-10-02 2001-05-20 Sankyo Co Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same
ATE258604T1 (de) 1998-02-17 2004-02-15 Searle & Co Verfahren zur enzymatischen auflösung von laktamen
PE20000564A1 (es) 1998-06-08 2000-07-05 Schering Corp Antagonistas receptores y5 de neuropeptidos
US6426331B1 (en) 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
CN1206219C (zh) 1998-12-18 2005-06-15 布里斯托尔-迈尔斯斯奎布药品公司 作为趋化因子受体活性调节剂的n－脲基烷基－哌啶化合物
EP1035115B1 (fr) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1
JP4070957B2 (ja) 1999-02-24 2008-04-02 エフ．ホフマン−ラ ロシュ アーゲー フェニルおよびピリジニル誘導体
PT1157005E (pt) 1999-02-24 2005-02-28 Hoffmann La Roche Derivados de 3-fenilpirina e a sua utilizacao como antagonistas do receptor nk-1
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
EP1194417A1 (fr) 1999-06-18 2002-04-10 Bayer Ag Phenoxyfluoropyrimidines
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
AU2010601A (en) 1999-12-16 2001-07-03 Novartis Ag Organic compounds
CZ20022332A3 (cs) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
EP1253923A1 (fr) 2000-01-28 2002-11-06 Biogen, Inc. Compositions pharmaceutiques contenant des composes d'integrine anti-beta 1 et utilisations correspondantes
WO2001056989A2 (fr) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INHIBITEURS DU FACTEUR Xa CONTENANT DU PHENYLENE BIVALENT
US20010047100A1 (en) 2000-04-26 2001-11-29 Kjaersgaard Hans Joergen Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
WO2001083517A1 (fr) 2000-05-03 2001-11-08 Tularik Inc. Derives de dipeptides de liaison stat4 et stat6
US6499984B1 (en) 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
EP1268450A1 (fr) 2000-06-01 2003-01-02 Bristol-Myers Squibb Pharma Company Lactames substitues par des succinates cycliques en tant qu'inhibiteurs de la production de la proteine beta
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
KR20030030005A (ko) 2000-09-15 2003-04-16 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AU2002211379A1 (en) 2000-10-04 2002-04-15 The Children's Hospital Of Philadelphia Compositions and methods for treatment of cystic fibrosis
GB2367816A (en) 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
AU2002212282A1 (en) 2000-10-20 2002-05-06 Merck Patent G.M.B.H Chiral binaphthol derivatives
US6884782B2 (en) 2000-11-08 2005-04-26 Amgen Inc. STAT modulators
ATE478664T1 (de) 2000-12-01 2010-09-15 Eisai Inc Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
US6962674B2 (en) 2001-02-28 2005-11-08 Varian, Inc. Dissolution test apparatus
CA2442654A1 (fr) 2001-04-10 2002-10-10 Transtech Pharma, Inc. Sondes, dispositifs et methodes pour la mise au point de medicaments
EP1385577B1 (fr) 2001-04-23 2006-04-19 F. Hoffman-la Roche AG Utilisation d'antagonistes de recepteur de nk-1 contre l'hyperplasie benigne de la prostate
SK15432003A3 (sk) 2001-05-22 2004-05-04 Neurogen Corporation 5-Substituované 2-arylpyridíny
US20030083345A1 (en) 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
WO2003007888A2 (fr) 2001-07-20 2003-01-30 Adipogenix, Inc. Composes de modulation d'accumulation de graisse
EP1411928A1 (fr) 2001-07-20 2004-04-28 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
US7427623B2 (en) 2001-09-11 2008-09-23 Smithkline Beecham Corporation 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
JP2003155285A (ja) 2001-11-19 2003-05-27 Toray Ind Inc 環状含窒素誘導体
JP2003221386A (ja) 2001-11-26 2003-08-05 Takeda Chem Ind Ltd 二環性誘導体、その製造法およびその用途
EP1458382A1 (fr) 2001-12-21 2004-09-22 Novo Nordisk A/S Derives amide utiles en tant qu'activateurs de la glucokinase
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
CN1703395A (zh) 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
US20050215614A1 (en) 2002-10-15 2005-09-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
WO2004041163A2 (fr) 2002-10-30 2004-05-21 Merck & Co., Inc. Composes de piperidinyl cyclopentyl aryl benzylamide modulateurs de l'activite du recepteur de chimiokine
AU2003287449A1 (en) 2002-10-31 2004-05-25 Nanostream, Inc. Parallel detection chromatography systems
WO2004047974A1 (fr) 2002-11-26 2004-06-10 Universiteit Gent Procede et appareil pour la granulation continue par voie humide de materiau pulverulent
JP2006512338A (ja) 2002-12-12 2006-04-13 ファルマシア・コーポレーション マイトジェン活性化プロテインキナーゼ−活性化プロテインキナーゼ−２阻害剤としてのアミノシアノピリジンの使用法
EP1585739B1 (fr) 2003-01-06 2011-04-20 Eli Lilly And Company Arylcyclopropylacetamides substitues servant d'activateurs de glucokinase
EP2562158A1 (fr) 2003-02-10 2013-02-27 Vertex Pharmaceuticals Incorporated Procédés pour la préparation de n-hétéroaryl-N-aryl-aminés par mise en réaction d'un ester d'acide N-aryl-carbamique avec un halo-hétéroaryle et procédés analogues
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
EP1601657A1 (fr) * 2003-03-12 2005-12-07 Vertex Pharmaceuticals Incorporated Pyrazoles, modulateurs de transporteurs de cassettes de liaison a l'atp
EA200501710A1 (ru) 2003-04-30 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые карбоновые кислоты
DE602004022819D1 (de) * 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
ES2386721T3 (es) * 2003-06-27 2012-08-28 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compuestos de piridinio anfifilos , método de fabricación y utilización de los mismos
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
JP2005053902A (ja) 2003-07-18 2005-03-03 Nippon Nohyaku Co Ltd フェニルピリジン類、その中間体及びこれを有効成分とする除草剤
JP2007504271A (ja) 2003-09-05 2007-03-01 ニューロジェン・コーポレーション Ｃｒｆ１受容体リガンドである、ヘテロアリール縮合ピリジン類、ピラジン類及びピリミジン類
RU2006111093A (ru) * 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
KR100528925B1 (ko) * 2003-09-09 2005-11-15 삼성에스디아이 주식회사 방열시트 및 이를 구비한 플라즈마 디스플레이 장치
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
CA2540978A1 (fr) * 2003-10-08 2005-04-21 Vertex Pharmaceuticals Incorporated Modulateurs des transporteurs des cassettes de fixation de l'atp
EP1679069A4 (fr) 2003-10-21 2009-05-13 Dainippon Sumitomo Pharma Co Nouveau derive de piperidine
FR2861304B1 (fr) 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CA2545719A1 (fr) * 2003-11-14 2005-06-02 Vertex Pharmaceuticals Incorporated Thiazoles et oxazoles utiles en tant que modulateurs de transporteurs de type cassette de liaison a l'atp
EP1687001A2 (fr) 2003-11-19 2006-08-09 Glaxo Group Limited Utilisation d'inhibiteurs selectifs de cyclooxygenase-2 pour le traitement de troubles schizophreniques
JP3746062B2 (ja) 2003-12-05 2006-02-15 第一製薬株式会社 固形製剤およびその製造方法
ES2238001B1 (es) 2004-01-21 2006-11-01 Vita Cientifica, S.L. Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005074535A2 (fr) * 2004-01-30 2005-08-18 Eisai Co., Ltd. Inhibiteurs de cholinesterase pour des troubles de la colonne vertebrale
MXPA06008606A (es) 2004-01-30 2007-04-13 Vertex Pharma Moduladores de transportadores con casete de union a atp.
WO2005080348A1 (fr) 2004-02-19 2005-09-01 Banyu Pharmaceutical Co., Ltd. Nouveau dérivé de sulfonamide
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
WO2005115399A2 (fr) 2004-04-16 2005-12-08 Neurogen Corporation Imidazopyrazines, imidazopyridines, et imidazopyrimidines utilisees comme ligands du recepteur crf1
US7585885B2 (en) 2004-04-22 2009-09-08 Eli Lilly And Company Pyrrolidine derivatives useful as BACE inhibitors
WO2005108358A2 (fr) 2004-04-22 2005-11-17 Eli Lilly And Company Inhibiteurs de la bace
US20080138803A1 (en) 2004-06-01 2008-06-12 Galvan-Goldman Nee Galvan Barb Method of Detecting Cystic Fibrosis Associated Mutations
TWI428271B (zh) 2004-06-09 2014-03-01 Smithkline Beecham Corp 生產藥物之裝置及方法
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
PT1773816E (pt) * 2004-06-24 2015-04-29 Vertex Pharma Moduladores de transportadores de cassete de ligação de atp
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
JP2008504097A (ja) 2004-07-01 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ナノ粒子を含有する医薬組成物の調製
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
AU2005268030B2 (en) 2004-08-06 2009-02-19 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds
US20060069110A1 (en) 2004-09-27 2006-03-30 Andersen Denise L Substituted heterocyclic compounds and methods of use
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
JP5036126B2 (ja) 2004-10-19 2012-09-26 日医工株式会社 エバスチン経口投与用製剤
CA2587461A1 (fr) 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles pour traiter des troubles du systeme nerveux central
MX2007007133A (es) 2004-12-15 2007-08-08 Dompe Pha R Ma Spa Res & Mfg Derivados de acido 2-arilpropionico y composiciones farmaceuticas que los contienen.
JP4790260B2 (ja) 2004-12-22 2011-10-12 出光興産株式会社 アントラセン誘導体を用いた有機エレクトロルミネッセンス素子
EP1844003A4 (fr) 2005-01-27 2010-09-22 Astrazeneca Ab Nouveaux composes biaromatiques, inhibiteurs du recepteur p2x7
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
WO2006082952A1 (fr) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited Composé amide
JP5385605B2 (ja) 2005-03-11 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
TWI377206B (en) 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
EP1710246A1 (fr) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Macrocycles de sulfoximine-pyrmidine et leurs sels correspondants, leurs procédé de fabrication, et leurs utilisation pharmaceutique contre le cancer
AU2006236387A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl CB1 antagonists
CA2605300A1 (fr) 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Preparation et utilisation de derives de l'acide aryle alkyle dans le traitement de l'obesite
JP2008538561A (ja) 2005-04-20 2008-10-30 メルク エンド カムパニー インコーポレーテッド アンジオテンシンｉｉ受容体アンタゴニスト
EP1879875A1 (fr) 2005-04-22 2008-01-23 Wyeth Formes cristallines de {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}chlorhydrate amine
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
ATE533749T1 (de) * 2005-05-24 2011-12-15 Vertex Pharma Modulatoren von atp-bindenden kassettentransportern
EP1890694A4 (fr) 2005-06-02 2010-10-27 Bayer Cropscience Ag Derives heteroaryle phenylalkyle substitues
JP2008543919A (ja) 2005-06-21 2008-12-04 アステックス・セラピューティクス・リミテッド 医薬化合物
US7316624B2 (en) * 2005-07-29 2008-01-08 Karsten Manufacturing Corporation Golf club head for a hybrid golf club
MX2008002019A (es) 2005-08-11 2008-04-16 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
ES2367844T3 (es) 2005-08-11 2011-11-10 Vertex Pharmaceuticals, Inc. Moduladores del regulador de la conductancia transmembrana de la fibrosis quística.
AU2006289281B2 (en) 2005-09-09 2012-05-17 KaNDy Therapeutics Ltd. Pyridine derivatives and their use in the treatment of psychotic disorders
WO2007039420A1 (fr) 2005-09-23 2007-04-12 F. Hoffmann-La Roche Ag Nouvelle forme galénique
AU2006302371A1 (en) * 2005-10-06 2007-04-19 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
EP1940821B1 (fr) 2005-10-19 2013-03-20 Grünenthal GmbH Nouveaux ligands du recepteur vanilloide et leur utilisation dans la production de medicaments
WO2007054480A1 (fr) 2005-11-08 2007-05-18 N.V. Organon Derives bisarylique de 2-(benzimidazol-1-yl)-acetamide et leur utilisation comme inhibiteurs du recepteur trpv1
SI2774925T1 (sl) 2005-11-08 2017-04-26 Vertex Pharmaceuticals Incorporated Heterociklični modulatorji prenašalcev z ATP-vezavno kaseto
US20120232059A1 (en) 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
EP1971606B1 (fr) 2005-12-05 2013-04-24 GlaxoSmithKline LLC Inhibiteurs d'erbb kinase de 2-pyrimidinyl-pyrazolopyridine
EP1979367A2 (fr) 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Derives de quinoline-4-one comme modulateurs de transporteurs abc
EP1974212A1 (fr) * 2005-12-27 2008-10-01 Vertex Pharmaceuticals Incorporated Composes utiles dans les bio-essais cftr et leurs procedes
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7691902B2 (en) 2005-12-28 2010-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
PL1993360T3 (pl) * 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
US8158059B2 (en) 2005-12-30 2012-04-17 Sotax Corporation Integrated dissolution processing and sample transfer system
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) * 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
SI3327016T1 (sl) 2006-04-07 2021-09-30 Vertex Pharmaceuticals Incorporated Priprava modulatorjev prenašalcev z ATP-vezavno kaseto
EP2021797B1 (fr) * 2006-05-12 2011-11-23 Vertex Pharmaceuticals, Inc. Compositions de n-ý2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl¨-1,4-dihydro-4-oxoquinoléine-3-carboxamide
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
ES2646175T3 (es) 2006-11-03 2017-12-12 Vertex Pharmaceuticals Incorporated Derivados de azaindol como moduladores de CFTR
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP5318400B2 (ja) 2006-11-20 2013-10-16 第一三共株式会社 レボフロキサシン含有錠剤
US20100075966A1 (en) 2006-11-27 2010-03-25 Novartis Ag Substituted Dihydroimidazoles and their Use in the Treatment of Tumors
CN101206205B (zh) 2006-12-22 2011-08-10 中国科学院大连化学物理研究所 微流量液相色谱在线大体积进样的方法和专用装置
CN101209399B (zh) 2006-12-27 2010-07-28 中国科学院沈阳应用生态研究所 一种往复式振荡机样品安放与固定装置
CN101210906A (zh) 2006-12-29 2008-07-02 电子科技大学 高通量自动化药物筛选实验检测系统
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20080279845A1 (en) 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet adp receptor inhibitor
CN102863432B (zh) 2007-05-09 2016-09-07 沃泰克斯药物股份有限公司 Cftr调节剂
CN101687883B (zh) 2007-05-25 2012-05-23 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
WO2009023509A2 (fr) 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Combinaisons thérapeutiques utiles pour traiter les maladies liées au cftr
JP5389030B2 (ja) * 2007-08-24 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
EP2222304A2 (fr) 2007-09-14 2010-09-01 Vertex Pharmaceuticals Incorporated Formes solides de n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoleine-3-carboxamide
AU2008298545B2 (en) 2007-09-14 2013-12-12 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
FR2921657A1 (fr) 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
ES2658064T3 (es) * 2007-11-16 2018-03-08 Vertex Pharmaceuticals Incorporated Moduladores de isoquinolina de transportadores de casete de unión a ATP
DE102007058718A1 (de) 2007-12-06 2009-06-10 Erweka Gmbh Vorrichtung und Verfahren zur automatischen Freisetzung und Messung von Wirkstoffen aus einer Arzneizubereitung
US20100036130A1 (en) * 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
KR101674404B1 (ko) * 2007-12-07 2016-11-09 버텍스 파마슈티칼스 인코포레이티드 사이클로알킬카복시아미도-피리딘 벤조산의 제조 방법
DK3170818T3 (da) * 2007-12-07 2020-04-14 Vertex Pharma Faste former af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
EP2237768A2 (fr) 2007-12-07 2010-10-13 Vertex Pharmaceuticals Incorporated Formulations d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
NZ586271A (en) 2007-12-13 2012-08-31 Vertex Pharma Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator
CN106432213A (zh) 2008-02-28 2017-02-22 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
EP2257356B1 (fr) 2008-02-29 2016-12-14 Waters Technologies Corporation Surveillance chromatographique et commande de plusieurs flux de traitement
ES2552990T3 (es) * 2008-03-31 2015-12-03 Vertex Pharmaceuticals Incorporated Derivados de piridilo como moduladores del CFTR
GB0813709D0 (en) 2008-07-26 2008-09-03 Univ Dundee Method and product
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
SI3345625T1 (sl) 2008-08-13 2021-04-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavek in njegove administracije
CN102164587A (zh) 2008-09-29 2011-08-24 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的剂量单元
US8436014B2 (en) * 2008-10-23 2013-05-07 Vertex Pharmaceutical Incorporated Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide
US20110257223A1 (en) * 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
ES2483690T3 (es) 2008-10-23 2014-08-07 Vertex Pharmaceuticals Incorporated Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US8314239B2 (en) * 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA2740836C (fr) 2008-10-31 2017-03-21 Biomerieux, Inc. Procedes pour la separation, la caracterisation et/ou l'identification de microorganismes a l'aide de la spectroscopie
JP5600322B2 (ja) 2008-11-06 2014-10-01 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセット輸送体のモジュレーター
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
JP5699090B2 (ja) * 2008-12-30 2015-04-08 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
SG174410A1 (en) 2009-03-20 2011-11-28 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
HUE038854T2 (hu) 2009-03-20 2018-12-28 Vertex Pharma Cisztás fibrózis transzmembrán konduktancia regulátor modulátorai
US9713575B2 (en) 2009-05-07 2017-07-25 Gea Process Engineering Limited Tablet production module and method for continuous production of tablets
KR20120083416A (ko) 2009-09-17 2012-07-25 버텍스 파마슈티칼스 인코포레이티드 아자비시클릭 화합물의 제조 방법
EP2813227A1 (fr) * 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions pour le traitement de la mucoviscidose et d'autres maladies chroniques
CN102648182A (zh) * 2009-10-23 2012-08-22 沃泰克斯药物股份有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
CA2778493A1 (fr) * 2009-10-23 2011-04-28 Vertex Pharmaceuticals Incorporated Formes solides de n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
NZ602557A (en) 2010-03-19 2014-09-26 Vertex Pharma Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
DK2826776T3 (da) * 2010-03-25 2020-12-14 Vertex Pharma Fast dispersion af amorf form af (r)-1(2,2-difluorbenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluor-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropancarboxamid
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
US8507687B2 (en) * 2010-04-07 2013-08-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2011133951A1 (fr) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
WO2011133953A1 (fr) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
CA2796646A1 (fr) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
KR20130056244A (ko) 2010-04-22 2013-05-29 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
EP2575814A1 (fr) * 2010-05-20 2013-04-10 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
AR081920A1 (es) * 2010-05-20 2012-10-31 Vertex Pharma Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
WO2012027247A2 (fr) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Composition pharmaceutique à base de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yle)cyclopropane carboxamide et son administration
US20120064157A1 (en) 2010-08-27 2012-03-15 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
KR101719699B1 (ko) * 2010-10-05 2017-03-27 삼성전자주식회사 메모리 모듈 및 이의 제조 방법
CN102058889A (zh) 2010-11-05 2011-05-18 王定豪 包含抗凝血类药物的分散片及其应用
US8802700B2 (en) * 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CN102507770A (zh) 2011-10-25 2012-06-20 中国检验检疫科学研究院 检测化妆品中六氯酚的高效液相色谱法
WO2013067410A1 (fr) 2011-11-02 2013-05-10 Vertex Pharmaceuticals Incorporated Utilisation de (n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoline-3-carboxamide) pour le traitement des maladies associées au gène cftr
JP6072056B2 (ja) 2011-11-08 2017-02-01 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｐ−結合カセットトランスポーターの修飾因子
US20140127901A1 (en) 2012-11-08 2014-05-08 Taiwan Semiconductor Manufacturing Company, Ltd. Low-k damage free integration scheme for copper interconnects
EP2806859B1 (fr) 2012-01-25 2019-05-15 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de l'acide 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yle) cyclopropane carboxamido)-3-méthylpyridin-2-yle) benzoïque et leur administration
US8798308B2 (en) * 2012-02-21 2014-08-05 Bose Corporation Convective airflow using a passive radiator
IL265430B2 (en) 2012-02-27 2024-08-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
US8674108B2 (en) * 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2013253790A (ja) 2012-06-05 2013-12-19 Chube Univ ニバレノールの分析法
AU2013270681A1 (en) 2012-06-08 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of CFTR -mediated disorders
EP2872122A1 (fr) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide et son administration
KR20200001619A (ko) * 2012-08-06 2020-01-06 피르메니히 인코포레이티드 단맛 향미 개질제
US20140092376A1 (en) 2012-10-01 2014-04-03 Momentive Performance Materials, Inc. Container and method for in-line analysis of protein compositions
FI2914248T4 (fi) * 2012-11-02 2023-12-19 Vertex Pharma Farmaseuttisia koostumuksia cftr-välitteisten tautien hoitamiseksi
US9636301B2 (en) 2012-12-04 2017-05-02 Arbutus Biopharma Corporation In vitro release assay for liposome encapsulated vincristine
US20140221424A1 (en) * 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
CN103743826B (zh) 2013-08-28 2015-12-02 合肥久诺医药科技有限公司 一种阿齐沙坦的高效液相色谱分析方法
CN103822976B (zh) 2013-10-15 2015-05-27 辽宁省食品药品检验所 一种测定化妆品中4-甲氧基水杨酸钾的方法
WO2015073231A1 (fr) 2013-11-12 2015-05-21 Vertex Pharmaceuticals Incorporated Procédé de préparation de compositions pharmaceutiques pour le traitement de maladies à médiation assurée par le cftr
FI3925607T3 (fi) 2014-04-15 2023-08-28 Vertex Pharma Farmaseuttisia koostumuksia kystisen fibroosin transmembraanisen konduktanssinsäätäjän välittämien tautien hoitamiseksi
CN104090038B (zh) 2014-07-07 2015-09-30 黄宏南 一种直接测定冬虫夏草产品中冬虫夏草多糖肽含量的方法
CN104122346B (zh) 2014-07-31 2016-03-16 国家烟草质量监督检验中心 一种水基胶中尿素含量的测定方法
CN104122345B (zh) 2014-07-31 2015-08-12 国家烟草质量监督检验中心 烟用纸中1,1,1-三羟甲基丙烷的测定方法
ES2702288T3 (es) 2014-10-07 2019-02-28 Vertex Pharma Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
JP6494757B2 (ja) 2014-11-18 2019-04-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ハイスループット試験高速液体クロマトグラフィーを行うプロセス
WO2016086136A1 (fr) 2014-11-26 2016-06-02 Catabasis Pharmaceuticals, Inc. Conjugués de cystéamine d'acide gras de modulateurs de cftr et leur utilisation dans le traitement de troubles médicaux
MA41031A (fr) 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
CA2969587A1 (fr) 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Composes pour le traitement de la fibrose kystique
WO2016123028A1 (fr) 2015-01-26 2016-08-04 Rigel Pharmaceuticals, Inc. Trétrazolones utilisées comme bioisostères d'acide carboxylique
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
CN105890945A (zh) 2016-04-01 2016-08-24 中国热带农业科学院分析测试中心 超声离心渗液进样快速测定土壤中速效钾的方法
US20180280349A1 (en) 2017-03-28 2018-10-04 Vertex Pharmaceuticals Incorporated Methods of treating cystic fibrosis in patients with residual function mutations

Also Published As

Publication number Publication date
US20120322798A1 (en) 2012-12-20
EP1945632A1 (fr) 2008-07-23
CN102775396A (zh) 2012-11-14
US20160143898A1 (en) 2016-05-26
US20180282311A9 (en) 2018-10-04
US20220153729A1 (en) 2022-05-19
US20130245010A1 (en) 2013-09-19
PL1945632T3 (pl) 2014-03-31
HK1125366A1 (en) 2009-08-07
KR20150041174A (ko) 2015-04-15
US7659268B2 (en) 2010-02-09
RU2463303C2 (ru) 2012-10-10
US7741321B2 (en) 2010-06-22
SI2774925T1 (sl) 2017-04-26
JP2009514962A (ja) 2009-04-09
ES2431388T3 (es) 2013-11-26
JP2014139243A (ja) 2014-07-31
KR101331768B1 (ko) 2013-11-22
US9216969B2 (en) 2015-12-22
EP2404919B1 (fr) 2013-08-21
RU2765714C2 (ru) 2022-02-02
US20170107206A1 (en) 2017-04-20
US20100087435A1 (en) 2010-04-08
AU2006311650A1 (en) 2007-05-18
EP3208272A1 (fr) 2017-08-23
US20100210638A1 (en) 2010-08-19
DK2774925T3 (en) 2017-02-27
CN102775396B (zh) 2014-10-08
RU2012123372A (ru) 2013-12-10
KR20130034062A (ko) 2013-04-04
US7973038B2 (en) 2011-07-05
KR20160067985A (ko) 2016-06-14
EP2774925B1 (fr) 2016-12-28
RU2463303C3 (ru) 2022-03-01
EP2395002A1 (fr) 2011-12-14
PT1945632E (pt) 2013-12-24
CY1115750T1 (el) 2017-01-25
US20190322650A1 (en) 2019-10-24
KR20140009566A (ko) 2014-01-22
US8993600B2 (en) 2015-03-31
CA2627358A1 (fr) 2007-05-18
CN101356170A (zh) 2009-01-28
SI1945632T1 (sl) 2014-03-31
US7956052B2 (en) 2011-06-07
ZA200803887B (en) 2009-12-30
KR101561482B1 (ko) 2015-10-20
US20080306062A1 (en) 2008-12-11
DK2404919T3 (da) 2013-11-04
US20210024505A1 (en) 2021-01-28
SI2395002T1 (sl) 2014-10-30
LT2774925T (lt) 2017-04-10
NO20082674L (no) 2008-08-07
EP3208272B1 (fr) 2020-01-08
PT2404919E (pt) 2013-10-22
PT2395002E (pt) 2014-09-16
DK1945632T3 (da) 2013-12-16
US8461156B2 (en) 2013-06-11
HUS1600023I1 (hu) 2016-06-28
KR20080066086A (ko) 2008-07-15
LTC2404919I2 (lt) 2017-12-27
PL2774925T3 (pl) 2017-07-31
US20080019915A1 (en) 2008-01-24
CY2016012I2 (el) 2016-10-05
JP5317184B2 (ja) 2013-10-16
CY2016012I1 (el) 2016-10-05
ES2619608T3 (es) 2017-06-26
RU2608610C2 (ru) 2017-01-23
RU2008122929A (ru) 2009-12-20
ES2439736T3 (es) 2014-01-24
US11084804B2 (en) 2021-08-10
PL2404919T3 (pl) 2014-01-31
DK2395002T3 (da) 2014-09-08
US8741933B2 (en) 2014-06-03
JP2015134835A (ja) 2015-07-27
JP5941095B2 (ja) 2016-06-29
SI2404919T1 (sl) 2013-12-31
CA2627358C (fr) 2015-10-06
JP2012233011A (ja) 2012-11-29
IL222784A (en) 2016-06-30
US20130245011A1 (en) 2013-09-19
NZ567892A (en) 2010-12-24
ES2778846T3 (es) 2020-08-12
ES2501594T3 (es) 2014-10-02
IL191141A (en) 2013-11-28
WO2007056341A1 (fr) 2007-05-18
CY1118768T1 (el) 2017-07-12
RU2016150386A3 (fr) 2020-02-26
EP2774925A1 (fr) 2014-09-10
US20080113985A1 (en) 2008-05-15
IL191141A0 (en) 2008-12-29
CN101356170B (zh) 2012-09-26
RU2016150386A (ru) 2018-06-21
US8324207B2 (en) 2012-12-04
US20110172229A1 (en) 2011-07-14
EP2404919A1 (fr) 2012-01-11
EP1945632B1 (fr) 2013-09-18
IL222784A0 (en) 2012-12-31
PT2774925T (pt) 2017-04-04
EP3696174A1 (fr) 2020-08-19
AU2006311650B2 (en) 2012-02-23
US20130237569A1 (en) 2013-09-12
US8318733B2 (en) 2012-11-27
HK1178892A1 (en) 2013-09-19
US20170107205A1 (en) 2017-04-20
US10626111B2 (en) 2020-04-21
HUE032640T2 (en) 2017-10-30
EP2395002B1 (fr) 2014-06-18
KR20130042034A (ko) 2013-04-25
US20130237568A1 (en) 2013-09-12
NL300812I2 (fr) 2016-09-26
JP5666525B2 (ja) 2015-02-12
US20110312958A1 (en) 2011-12-22
PL2395002T3 (pl) 2015-04-30

Similar Documents

Publication Publication Date Title
LU93073I2 (fr) Acide benzoïque 3-{6-{-1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl¦amino}-3-methylpyridin-2-yl}, ou un sel pahrmaceutiquement acceptable de celui-ci, ou un promédicament de type ester de celui-ci
NO2017009I1 (no) 3-{6-{[1-(2,2-difluor-1,3-benzodioksol-5-yl)cykopropankarbonyl]amino}-3-metylpyridin-2-yl}benzosyre
LU93327I2 (fr) Opicapone ou un sel pharmaceutiquement acceptable de celui-ci
NO20054958D0 (no) Substitulerte aminokarboksylsyrer
DE602006014036D1 (de) Triggerschalter
DK1702633T3 (da) Slagfaste plastmaterialer til proteser
NO20054957D0 (no) Subtituerte karboksylsyrer
ITTO20050016A1 (it) Macchina operatrice laser
DE602006017292D1 (de) Angetriebenes Schlagwerkzeug
DE602006018072D1 (de) Laserverarbeitungskopf
DE602006002145D1 (de) Sabotagekontaktanordnung
ITMI20051854A1 (it) Patch per la sostituzione di una porzione di parete vescicale a seguito di vescitectomia parziale
DE602006001073D1 (de) Viehmarke
BRPI0609066A2 (pt) composição de ácido tereftálico
DK1910325T3 (da) Nye farmaceutisk forbindelser
DK1711396T3 (da) Lokaliseringssignalenhed
ITBO20050111A1 (it) Macchina comprimitrice
DE502006005424D1 (de) Niveauwächtersystem
DE602005022545D1 (de) Rasenmäher
ITRM20050604A1 (it) Attrezzo sportivo.
FR2884253B1 (fr) Materiaux monolithiques fonctionnalisables
UY3546Q (es) Maquina de juego
UY3548Q (es) Maquina de juego
ITTO20040111A1 (it) Macchina per la compattazione rifiuti
FI20050298A (fi) Menetelmä protrombiiniajan määrittämiseksi